Floatz logo

Tak-659

Advanced Solid Neoplasms

Calithera Biosciences, IncPhase 1Dormant
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
16/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced Solid Neoplasms cohort.

Asset / SponsorPhaseRating
Olaparib
Merck Sharp & Dohme LLC
Phase 2CCC
AGONISTIC ANTI-CD40 MONOCLONAL ANTIBODY ADC-1013
Janssen Research & Development, LLC
Phase 1CC

Same molecule, other indications

Tak-659 is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →